Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Nia Impact Advisors LLC

Nia Impact Advisors LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,932 shares of the pharmaceutical company’s stock after selling 1,395 shares during the period. Vertex Pharmaceuticals comprises about 2.1% of Nia Impact Advisors LLC’s portfolio, making the stock its 16th largest holding. Nia Impact Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $6,416,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. ABC Arbitrage SA purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $1,510,000. Highview Capital Management LLC DE increased its holdings in Vertex Pharmaceuticals by 1.8% in the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company’s stock valued at $2,324,000 after purchasing an additional 102 shares during the last quarter. Davidson Investment Advisors increased its holdings in Vertex Pharmaceuticals by 26.0% in the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company’s stock valued at $24,630,000 after purchasing an additional 12,631 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in Vertex Pharmaceuticals by 75.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company’s stock valued at $994,000 after purchasing an additional 1,062 shares during the last quarter. Finally, Concord Wealth Partners increased its holdings in Vertex Pharmaceuticals by 32.6% in the 4th quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock valued at $1,413,000 after purchasing an additional 862 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Wolfe Research downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an “overweight” rating in a report on Tuesday, May 6th. The Goldman Sachs Group restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Royal Bank of Canada boosted their price target on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a “sector perform” rating in a research note on Tuesday, May 6th. Thirteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $432.00 on Wednesday. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The company has a market cap of $110.94 billion, a P/E ratio of -196.36, a P/E/G ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The firm’s 50 day moving average is $486.62 and its two-hundred day moving average is $465.33.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same period in the prior year, the business posted $4.76 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Activity

In related news, EVP Ourania Tatsis sold 244 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. This trade represents a 0.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Altshuler sold 3,231 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. The trade was a 10.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,005 shares of company stock valued at $1,978,465. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.